Ovid Therapeutics Inc
OVID1.740USD
+0.270+18.37%
Market hours （ET）Quotes delayed by 15 min
123.80MMarket Cap
LossP/E TTM
More Details of Ovid Therapeutics Inc Company
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Ovid Therapeutics Inc Info
Ticker SymbolOVID
Company nameOvid Therapeutics Inc
IPO dateMay 05, 2017
CEOAlexander (Margaret A)
Number of employees23
Security typeOrdinary Share
Fiscal year-endMay 05
Address441 Ninth Avenue, 14Th Floor
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10001
Phone12127764381
Websitehttps://ovidrx.com/
Ticker SymbolOVID
IPO dateMay 05, 2017
CEOAlexander (Margaret A)
Company Executives of Ovid Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
200.00K
--
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Jeffrey Rona
Mr. Jeffrey Rona
Chief Business and Financial Officer
Chief Business and Financial Officer
--
--
Ms. Margaret (Meg) Alexander
Ms. Margaret (Meg) Alexander
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
200.00K
--
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Dec 21
Updated: Sun, Dec 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
15.05%
Takeda Pharmaceutical Co Ltd
12.33%
Affinity Asset Advisors LLC
10.04%
Levin (Jeremy M)
5.13%
The Vanguard Group, Inc.
3.96%
Other
53.49%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
15.05%
Takeda Pharmaceutical Co Ltd
12.33%
Affinity Asset Advisors LLC
10.04%
Levin (Jeremy M)
5.13%
The Vanguard Group, Inc.
3.96%
Other
53.49%
Shareholder Types
Shareholders
Proportion
Hedge Fund
25.16%
Venture Capital
15.30%
Corporation
12.33%
Investment Advisor
9.59%
Investment Advisor/Hedge Fund
8.89%
Individual Investor
5.51%
Research Firm
2.77%
Other
20.44%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
176
23.96M
33.70%
-28.43M
2025Q2
176
46.12M
64.86%
-16.45M
2025Q1
183
51.39M
72.29%
-10.07M
2024Q4
181
52.28M
73.63%
-8.46M
2024Q3
175
51.32M
72.31%
-10.19M
2024Q2
172
51.56M
72.67%
-6.81M
2024Q1
174
55.84M
78.97%
-6.53M
2023Q4
174
57.32M
81.09%
-4.46M
2023Q3
183
57.79M
81.95%
-5.02M
2023Q2
192
56.05M
79.62%
-3.53M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Takeda Pharmaceutical Co Ltd
7.53M
10.59%
--
--
Jun 30, 2025
Affinity Asset Advisors LLC
667.52K
0.94%
--
--
Jun 30, 2025
Levin (Jeremy M)
3.65M
5.14%
-20.00
-0.00%
Apr 24, 2025
The Vanguard Group, Inc.
2.64M
3.71%
-472.67K
-15.20%
Jun 30, 2025
Acadian Asset Management LLC
2.11M
2.96%
+20.29K
+0.97%
Jun 30, 2025
Renaissance Technologies LLC
2.10M
2.95%
+1.07M
+104.66%
Jun 30, 2025
Sio Capital Management, LLC
2.23M
3.14%
--
--
Jun 30, 2025
Driehaus Capital Management, LLC
1.40M
1.97%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
1.15M
1.62%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco Nasdaq Biotechnology ETF
0%
Fidelity Enhanced Small Cap ETF
0%
ProShares Hedge Replication ETF
0%
Avantis Responsible US Equity ETF
0%
View more
iShares Russell 2000 Growth ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Avantis Responsible US Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Ovid Therapeutics Inc?
The top five shareholders of Ovid Therapeutics Inc are:
Takeda Pharmaceutical Co Ltd holds 7.53M shares, accounting for 10.59% of the total shares.
Affinity Asset Advisors LLC holds 667.52K shares, accounting for 0.94% of the total shares.
Levin (Jeremy M) holds 3.65M shares, accounting for 5.14% of the total shares.
The Vanguard Group, Inc. holds 2.64M shares, accounting for 3.71% of the total shares.
Acadian Asset Management LLC holds 2.11M shares, accounting for 2.96% of the total shares.
Takeda Pharmaceutical Co Ltd holds 7.53M shares, accounting for 10.59% of the total shares.
Affinity Asset Advisors LLC holds 667.52K shares, accounting for 0.94% of the total shares.
Levin (Jeremy M) holds 3.65M shares, accounting for 5.14% of the total shares.
The Vanguard Group, Inc. holds 2.64M shares, accounting for 3.71% of the total shares.
Acadian Asset Management LLC holds 2.11M shares, accounting for 2.96% of the total shares.
What are the top three shareholder types of Ovid Therapeutics Inc?
The top three shareholder types of Ovid Therapeutics Inc are:
RA Capital Management, LP
Takeda Pharmaceutical Co Ltd
Affinity Asset Advisors LLC
RA Capital Management, LP
Takeda Pharmaceutical Co Ltd
Affinity Asset Advisors LLC
How many institutions hold shares of Ovid Therapeutics Inc (OVID)?
As of 2025Q3, 176 institutions hold shares of Ovid Therapeutics Inc, with a combined market value of approximately 23.96M, accounting for 33.70% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -31.16%.
What is the biggest source of revenue for Ovid Therapeutics Inc?
In --, the -- business generated the highest revenue for Ovid Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
